Mirae Asset Global Investments Co., Ltd. 2seventy Bio, Inc. Transaction History

Mirae Asset Global Investments Co., Ltd.

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 01, 2024	BUY	$3.09 - $6.0 $209,869 - $407,514	67,919 Added 85.99%	146,901 $785,000
Q4 2023 Jan 24, 2024	SELL	$1.57 - $4.58 $265,160 - $773,525	-168,892 Reduced 68.14%	78,982 $337,000
Q3 2023 Oct 26, 2023	BUY	$3.14 - $11.2 $82,845 - $295,500	26,384 Added 11.91%	247,874 $971,000
Q2 2023 Aug 10, 2023	BUY	$8.45 - $12.48 $541,560 - $799,843	64,090 Added 40.72%	221,490 $2.24 Million
Q1 2023 May 04, 2023	BUY	$9.21 - $14.98 $88,498 - $143,942	9,609 Added 6.5%	157,400 $1.61 Million
Q4 2022 Feb 09, 2023	SELL	$8.57 - $17.0 $369,718 - $733,397	-43,141 Reduced 22.59%	147,791 $1.38 Million
Q3 2022 Nov 10, 2022	BUY	$12.56 - $17.54 $311,035 - $434,360	24,764 Added 14.9%	190,932 $2.78 Million
Q2 2022 Jul 26, 2022	BUY	$10.55 - $18.81 $1 Million - $1.79 Million	95,062 Added 133.69%	166,168 $2.19 Million
Q1 2022 Jun 02, 2022	BUY	$11.67 - $26.72 $829,807 - $1.9 Million	71,106 New	71,106 $1.21 Million
Q1 2022 May 10, 2022	SELL	$11.67 - $26.72 $1.01 Million - $2.31 Million	-86,621 Closed	0 $0
Q4 2021 Feb 08, 2022	BUY	$13.77 - $42.56 $1.19 Million - $3.69 Million	86,621 New	86,621 $2.22 Million

126

45.6M

122K

19.8K

Ticker TSVT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 37,873,600
Market Cap $137M
Description
2seventy bio, Inc., a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. Its products pipeline includes idecabtagene vicleucel; ide-cel or Abecma and bb21217; and CAR-T cell product candidates for the treatment of multiple myeloma. 2seventy bio, Inc. has a col...

Get notified when there are updates to the investment portfolio of Mirae Asset Global Investments Co., Ltd., based on Form 13F filings with the SEC.

Stay updated on Mirae Asset Global Investments Co., Ltd. with notifications on news.